Compare Strategy Inc. (MSTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Strategy Inc. trades at $131.41 (market cap $54.24B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: Strategy Inc. is far larger — about 31.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| MSTR | RXRX | |
|---|---|---|
Market Cap | $54.24B | $1.74B |
Sector | Technology | Health |
52-Week High | $359.69 | $6.79 |
52-Week Low | $82.31 | $2.84 |
Enterprise Value | $73.00B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $136.52, down 4.4% today, with a bullish technical signal from moving averages and support at $135. The company reported Q2 2026 EPS of -$24.45, missing expectations, and has a negative net income margin of -6,102.96%. Recent news highlights MSTR's partnership with Google Cloud for AI forums and a shift in capital allocation toward preferred stock buybacks instead of Bitcoin purchases.
Outlook remains speculative with high volatility; analyst consensus is bullish with a $229.64 price target, but risks include persistent earnings misses, heavy debt, and dependence on Bitcoin's performance. Institutional sentiment is mixed amid operational cash flow challenges and competitive pressures in software services.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
